Citadel Advisors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Citadel Advisors’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,200	Closed	-$241K	–	8885
2017 Q3	$241K	Sell	6,200 -1,800	-23%	-$66.2K	﹤0.01%	6407
2017 Q2	$239K	Sell	8,000 -3,200	-29%	-$82.9K	﹤0.01%	6287
2017 Q1	$297K	Buy	+11,200	New	+$277K	﹤0.01%	5897
2016 Q3	–	Sell	-17,300	Closed	-$281K	–	8360
2016 Q2	$281K	Buy	+17,300	New	+$291K	﹤0.01%	5315

Other funds holding NDRM

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Citadel Advisors's NDRM Position: Q3 2017 in Review

Citadel Advisors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 341,526 shares — an estimated $12.6M sold.

Citadel Advisors first reported a position in NDRM in Q4 2014 and held it in 3 quarters. The position peaked at $10.2M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

Citadel Advisors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Citadel Advisors sold 341,526 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $12.6M.
Citadel Advisors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 3 quarters.
Citadel Advisors's NeuroDerm Ltd. Ordinary Shares position peaked at $10.2M in Q2 2017.
81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.